Investigating the Mechanism of FMS-Like Tyrosine Kinase 3 (FLT3) Inhibitors in Acute Myeloid Leukemia (AML): A Basic and Clinical Research
- سال انتشار: 1397
- محل انتشار: نخستین همایش جامع بین المللی علوم پزشکی، داروسازی و پرستاری
- کد COI اختصاصی: MPNI01_031
- زبان مقاله: انگلیسی
- تعداد مشاهده: 545
نویسندگان
Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
School of Medicine, Hamedan University of Medical Sciences, Hamedan, Iran
Department of Genetics, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background & Objectives: The FMS-like tyrosine kinase 3 (FLT3) pathways can play a significant role in cellular proliferation, survival, and differentiation. In this respect, patients with acute myeloid leukemia (AML) with mutated FLT3 suffer from high levels of disease burden at presentation and dismal prognosis. In this respect, several FLT3 inhibitors have been developed and used to treat patients affected with FLT3-mutated AML in all disease contexts including induction, consolidation, maintenance, relapse, and hematopoietic cell transplantation (HCT).Methodology: To this end, a search was conducted in relevant English articles in the literature published in the database of PubMed using the keywords of AML, FLT3 Inhibitors, FLT3-ITD, FLT3 _TKI, Treatment.Findings: The findings showed that numerous inhibitors of FLT3 signaling had been recognized and also reported in clinical trials, both alone and with chemotherapy, which could improve clinical outcomes in patients with AML with FLT3 mutations. The first-generation type I inhibitor such as midostaurin also had benefits and the second-generation type I inhibitors such as gilteritinib was reported favorable as new combinations of diverse therapies had been advocated to increase the effect of FLT3 inhibitors and to prevent resistance or even control it. Accordingly, FLT3 tyrosine kinase inhibitors (TKI) were found as a new therapeutic option in internal tandem duplications (FLT3-ITD) AML, and clinical trials were also being conducted with various types of TKI either alone, combined with chemotherapy, or as maintenance after allogenic stem cell transplantation. Conclusion: FLT3 inhibitors had significant anti-leukemic activities in clinical trials; however, sustained remissions using these inhibitors as monotherapy had not been obtained. Furthermore, efficacy of TKI treatment of relapsed or refractory FLT3-ITD AML was limited and needed improvements; e.g., through the introduction of the second-generation inhibitors targeting constitutively active FLT3.کلیدواژه ها
AML, FLT3 Inhibitors, FLT3-ITD, FLT3 _TKI, Treatmentمقالات مرتبط جدید
- بررسی رابطه میزان قدرت ارتباطی با جوانی جمعیت (مطالعه موردی: دانشجویان رشته روانشناسی دانشگاه آزاد اسلامی واحد دامغان)
- رسیدگی به سقط درمانی و بازنگری قضایی آن
- درمان ناباروری با روش IVF
- اثر حفاظتی و بهبود دهندگی برخی گیاهان دارویی به عنوان آنتی اکسیدان های طبیعی بر کیفیت اسپرم های منجمد - یخ گشایی شده
- مروری بر بررسی اثر بخشی روش های کمک باروری با محوریت القاء تخمک گذاری در درمان زنان ناباور
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.